Lupin Limited has informed the Exchange regarding 'U.S. FDA has conducted a product-specific Pre-Approval Inspection at the Company s Chhatrapati Sambhajinagar (Aurangabad) manufacturing facility '.
LUPIN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Lupin has informed the exchange that the U.S. FDA carried out a product-specific Pre-Approval Inspection (PAI) at its Chhatrapati Sambhajinagar (formerly Aurangabad) manufacturing plant. A PAI is conducted by the FDA before clearing a new product (typically an ANDA) for the U.S. market and is a critical step in the approval timeline. The company has not disclosed any Form 483 observations or warning letter in this filing. The Aurangabad site is one of Lupin's key facilities supplying the U.S., its largest market by revenue. The inspection outcome, if clean, would enable timely launches of pending products.
This is a routine regulatory milestone, not an approval itself. A clean inspection supports upcoming U.S. product launches and revenue growth, while adverse observations could delay approvals and pressure the stock. Investors should watch for the inspection closure report.